This current study confirms the findings on the extension of telomeres in a randomized, double-blind, placebo-controlled in vivo (human) study of TA-65® over a period of one year.
This study was conducted with 117 relatively healthy CMV (cytomegalovirus) - positive subjects aged 53 to 87 years carried out .
Patients taking the low dose (250 units/day) over 12 months had significantly increased telomere length, while patients in the placebo group lost telomere length.
The results suggest that TA-65® lengthens telomeres in a statistically and possibly clinically significant manner.
Pub Med 3/2016, English (PDF) read here
